GILEAD SCIENCES, INC. Available-for-sale Securities, Gross Realized Gains
GILEAD SCIENCES, INC. (GILD) reported Available-for-sale Securities, Gross Realized Gains of $1.00 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-25.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGains · last filed 2015-02-25
- GILEAD SCIENCES, INC. available-for-sale securities, gross realized gains for the quarter ending 2014-12-31 was $135.00K, a 61.21% decline year-over-year.
- GILEAD SCIENCES, INC. available-for-sale securities, gross realized gains for the quarter ending 2014-09-30 was $164.00K, a 39.03% decline year-over-year.
- GILEAD SCIENCES, INC. available-for-sale securities, gross realized gains for the quarter ending 2014-06-30 was $363.00K, a 80.60% increase year-over-year.
- GILEAD SCIENCES, INC. available-for-sale securities, gross realized gains for the quarter ending 2014-03-31 was $338.00K, a 85.71% increase year-over-year.
- GILEAD SCIENCES, INC. available-for-sale securities, gross realized gains for fiscal 2014 was $1.00M, a 0.00% change from fiscal 2013.
- GILEAD SCIENCES, INC. available-for-sale securities, gross realized gains for fiscal 2013 was $1.00M, a 90.00% decline from fiscal 2012.
- GILEAD SCIENCES, INC. available-for-sale securities, gross realized gains for fiscal 2012 was $10.00M, a 76.66% decline from fiscal 2011.
- GILEAD SCIENCES, INC. available-for-sale securities, gross realized gains for fiscal 2011 was $42.85M, a 223.29% increase from fiscal 2010.
| Period end | Available-for-sale Securities, Gross Realized Gains 3 month | Available-for-sale Securities, Gross Realized Gains 6 month | Available-for-sale Securities, Gross Realized Gains 9 month | Available-for-sale Securities, Gross Realized Gains 12 month | Available-for-sale Securities, Gross Realized Gains 12 month as first filed |
|---|---|---|---|---|---|
| 2014-12-31 | $135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $299.00K derived: sum of 2 quarters · filed 2015-02-25 | $662.00K derived: sum of 3 quarters · filed 2015-02-25 | $1.00M 10-K · filed 2015-02-25 | |
| 2014-09-30 | $164.00K 10-Q · filed 2014-11-05 | $527.00K derived: sum of 2 quarters · filed 2014-11-05 | $865.00K 10-Q · filed 2014-11-05 | $1.21M derived: sum of 4 quarters · filed 2015-02-25 | |
| 2014-06-30 | $363.00K 10-Q · filed 2014-08-04 | $701.00K 10-Q · filed 2014-08-04 | $1.05M derived: sum of 3 quarters · filed 2015-02-25 | $1.32M derived: sum of 4 quarters · filed 2015-02-25 | |
| 2014-03-31 | $338.00K 10-Q · filed 2014-05-07 | $686.00K derived: sum of 2 quarters · filed 2015-02-25 | $955.00K derived: sum of 3 quarters · filed 2015-02-25 | $1.16M derived: sum of 4 quarters · filed 2015-02-25 | |
| 2013-12-31 | $348.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | $617.00K derived: sum of 2 quarters · filed 2015-02-25 | $818.00K derived: sum of 3 quarters · filed 2015-02-25 | $1.00M 10-K · filed 2015-02-25 | $1.31M 10-K · filed 2014-02-25 |
| 2013-09-30 | $269.00K 10-Q · filed 2014-11-05 | $470.00K derived: sum of 2 quarters · filed 2014-11-05 | $652.00K 10-Q · filed 2014-11-05 | $528.00K derived: sum of 4 quarters · filed 2015-02-25 | |
| 2013-06-30 | $201.00K 10-Q · filed 2014-08-04 | $383.00K 10-Q · filed 2014-08-04 | $259.00K derived: sum of 3 quarters · filed 2015-02-25 | $284.00K derived: sum of 4 quarters · filed 2015-02-25 | |
| 2013-03-31 | $182.00K 10-Q · filed 2014-05-07 | $58.00K derived: sum of 2 quarters · filed 2015-02-25 | $83.00K derived: sum of 3 quarters · filed 2015-02-25 | $167.00K derived: sum of 4 quarters · filed 2015-02-25 | |
| 2012-12-31 | -$124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25 | -$99.00K derived: sum of 2 quarters · filed 2015-02-25 | -$15.00K derived: sum of 3 quarters · filed 2015-02-25 | $10.00M 10-K · filed 2015-02-25 | $10.45M 10-K · filed 2013-02-27 |
| 2012-09-30 | $25.00K 10-Q · filed 2013-10-31 | $109.00K derived: sum of 2 quarters · filed 2013-10-31 | $10.12M 10-Q · filed 2013-10-31 | $39.19M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-06-30 | $84.00K 10-Q · filed 2013-08-01 | $10.10M 10-Q · filed 2013-08-01 | $39.16M derived: sum of 3 quarters · filed 2014-02-25 | $43.99M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-03-31 | $10.02M 10-Q · filed 2013-05-08 | $39.08M derived: sum of 2 quarters · filed 2014-02-25 | $43.91M derived: sum of 3 quarters · filed 2014-02-25 | $49.17M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2011-12-31 | $29.07M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $33.90M derived: sum of 2 quarters · filed 2014-02-25 | $39.15M derived: sum of 3 quarters · filed 2014-02-25 | $42.85M 10-K · filed 2014-02-25 | |
| 2011-09-30 | $4.83M 10-Q · filed 2012-11-06 | $10.09M derived: sum of 2 quarters · filed 2012-11-06 | $13.78M 10-Q · filed 2012-11-06 | $16.45M derived: sum of 4 quarters · filed 2013-02-27 | |
| 2011-06-30 | $5.26M 10-Q · filed 2012-08-01 | $8.95M 10-Q · filed 2012-08-01 | $11.62M derived: sum of 3 quarters · filed 2013-02-27 | $12.91M derived: sum of 4 quarters · filed 2013-02-27 | |
| 2011-03-31 | $3.70M 10-Q · filed 2012-05-04 | $6.36M derived: sum of 2 quarters · filed 2013-02-27 | $7.65M derived: sum of 3 quarters · filed 2013-02-27 | $15.12M derived: sum of 4 quarters · filed 2013-02-27 | |
| 2010-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $3.96M derived: sum of 2 quarters · filed 2013-02-27 | $11.42M derived: sum of 3 quarters · filed 2013-02-27 | $13.25M 10-K · filed 2013-02-27 | |
| 2010-09-30 | $1.29M 10-Q · filed 2011-11-04 | $8.75M derived: sum of 2 quarters · filed 2011-11-04 | $10.59M 10-Q · filed 2011-11-04 | $11.85M derived: sum of 4 quarters · filed 2012-02-23 | |
| 2010-06-30 | $7.46M 10-Q · filed 2011-08-05 | $9.30M 10-Q · filed 2011-08-05 | $10.56M derived: sum of 3 quarters · filed 2012-02-23 | $12.30M derived: sum of 4 quarters · filed 2012-02-23 | |
| 2010-03-31 | $1.83M 10-Q · filed 2011-05-09 | $3.10M derived: sum of 2 quarters · filed 2012-02-23 | $4.83M derived: sum of 3 quarters · filed 2012-02-23 | $7.27M derived: sum of 4 quarters · filed 2012-02-23 | |
| 2009-12-31 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23 | $3.00M derived: sum of 2 quarters · filed 2012-02-23 | $5.43M derived: sum of 3 quarters · filed 2012-02-23 | $10.37M 10-K · filed 2012-02-23 | |
| 2009-09-30 | $1.73M 10-Q · filed 2010-11-08 | $4.17M derived: sum of 2 quarters · filed 2010-11-08 | $9.11M 10-Q · filed 2010-11-08 | ||
| 2009-06-30 | $2.44M 10-Q · filed 2010-08-09 | $7.37M 10-Q · filed 2010-08-09 | |||
| 2008-12-31 | $28.37M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |